Oral News and Research

RSS

Phase 2 INNOVATE PCI trial results for elinogrel presented

Phase 2 trial results for elinogrel, a novel antiplatelet agent available in both intravenous and oral formulations, were presented here today.

30 Aug 2010

Opinions: MDG progress; Drug patents; Aid for scientific research; Avoiding food crises; Hunger in India; U.S. commitments to PEPFAR, Global Fund

"Between the catastrophes of the Haiti earthquake and the Pakistan floods, there was actually some good news this spring on the global health front, which offers hope that the United Nations' ambitious Millennium Development Goals might not be at a standstill. Though a great deal remains to be done, all of us are living longer, fewer mothers are dying in childbirth, and fewer children are dying before school age," Eli Adashi, professor of medical science at Brown University, writes in Boston Globe editorial.

30 Aug 2010

BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010

BioDelivery Sciences International, Inc. announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating frontline clinicians who are faced with treating patients with pain. The presentation will take place on Friday, September 10, as part of the 7:00 - 9:00 AM podium presentation session.

30 Aug 2010

Trius commences oral torezolid phosphate Phase 3 clinical study for ABSSSI

Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.

30 Aug 2010

Researchers find smoked cannabis reduces chronic neuropathic pain

For people suffering chronic pain, smoked cannabis reduces pain, improves mood and helps sleep, according to new research published in CMAJ.

30 Aug 2010

TEMSO Phase III Trial shows ARR reduction in multiple sclerosis patients

Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial.

30 Aug 2010

Study reveals impact of genetic make-up on response to oral antiplatelet treatment ticagrelor

A new genetic substudy of PLATO showed that the effects on a combined primary endpoint of cardiovascular death, myocardial infarction, or stroke seen in Acute Coronary Syndromes patients who received the investigational oral antiplatelet treatment, ticagrelor (BRILINTA), were maintained, whether or not they had the genetic variability that has been previously shown to affect a patient's response to clopidogrel.

30 Aug 2010

Sermo report highlights physician opinions about investigational oral antiplatelet treatment for ACS

Sermo, the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome.

26 Aug 2010

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

Chelsea Therapeutics International, Ltd. announced confirmation by the U.S. Food and Drug Administration (FDA) that its proposed Phase II protocol for CH-4051 in rheumatoid arthritis has been approved by the agency.

26 Aug 2010

Study finds 90% of adult population of Valencia have cavities

A research study has for the first time revealed data about dental cavities, periodontal disease, oral treatment needs, the use of dental prostheses and dental hygiene habits among the adult population in the Valencia region. The results show that 90% of people have cavities and 20-35% need prostheses.

26 Aug 2010

PLX4032 therapy results in tumor shrinkage in metastatic melanoma patients

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma.

26 Aug 2010

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.

25 Aug 2010

Tranzyme Pharma to present ulimorelin Phase 2 data at NGM Meeting

Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine, Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present ulimorelin Phase 2 data at this year's Joint International NGM Meeting on Saturday, August 28, 2010.

25 Aug 2010

Pen-size plasma sterilization device

Prof. Jiunn-Der Liao of Department of Materials Science and Engineering at National Cheng Kung University (NCKU), Tainan, Taiwan, has led Post Doctorate Chih-Chiang Weng and a research team to develop a pen-size plasma sterilization device which can sterilize instruments and wounds by relying on the process of plasma sterilization.

25 Aug 2010

Fluoridation exposure during childhood prevents adult tooth loss

Children drinking water with added fluoride helps dental health in adulthood decades later, a new study finds.

25 Aug 2010

Advanced Life Sciences seeks government funding for development of Restanza antibiotic

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced plans to seek additional government funding for development of its novel, once-daily antibiotic, Restanza.

25 Aug 2010

Parents should give their children's lunches a sugar makeover: Delta Dental Plans Association

As parents send their kids off for the first day of school, it's a good idea to put as much thought into what they're packing in their kids' lunchboxes as they do into their school supplies.

25 Aug 2010

Access Pharmaceuticals to highlight Cobalamin nanotechnology at ACS National Meeting

ACCESS PHARMACEUTICALS, INC.,a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Director of Chemistry and Quality, Dr. Ric Zarzycki will give an invited presentation today on the Company's Cobalamin nanoparticle technology at a thought-leadership symposium being held at the American Chemical Society's ("ACS") 240th National Meeting & Exposition, at Boston Convention and Exhibition Center in Boston, Massachusetts, August 22-26, 2010.

25 Aug 2010

Ensemble Therapeutics showcases data on new drug discovery platform at ACS National Meeting

Ensemble Therapeutics announced today the presentation of data on its macrocyclic-based drug discovery platform at the American Chemical Society National Meeting August 22-26, in Boston at the Boston Convention and Exposition Center.

24 Aug 2010

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Alnylam Pharmaceuticals, Inc.,a leading RNAi therapeutics company, announced today that it will make a total of 16 oral presentations at the American Chemical Society (ACS) Fall 2010 240th National Meeting & Exposition being held in Boston, Mass. from August 22-26, 2010.

24 Aug 2010

Oral News and Research

Phase 2 INNOVATE PCI trial results for elinogrel presented

Opinions: MDG progress; Drug patents; Aid for scientific research; Avoiding food crises; Hunger in India; U.S. commitments to PEPFAR, Global Fund

BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010

Trius commences oral torezolid phosphate Phase 3 clinical study for ABSSSI

Researchers find smoked cannabis reduces chronic neuropathic pain

TEMSO Phase III Trial shows ARR reduction in multiple sclerosis patients

Study reveals impact of genetic make-up on response to oral antiplatelet treatment ticagrelor

Sermo report highlights physician opinions about investigational oral antiplatelet treatment for ACS

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

Study finds 90% of adult population of Valencia have cavities

PLX4032 therapy results in tumor shrinkage in metastatic melanoma patients

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Tranzyme Pharma to present ulimorelin Phase 2 data at NGM Meeting

Pen-size plasma sterilization device

Fluoridation exposure during childhood prevents adult tooth loss

Advanced Life Sciences seeks government funding for development of Restanza antibiotic

Parents should give their children's lunches a sugar makeover: Delta Dental Plans Association

Access Pharmaceuticals to highlight Cobalamin nanotechnology at ACS National Meeting

Ensemble Therapeutics showcases data on new drug discovery platform at ACS National Meeting

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News